Clinical Trials Logo
  1. Home
  2. Hand-foot Syndrome
  3. NCT04979078

Photobiomodulation Therapy in the Management of Hand-foot Syndrome and Hand-foot Skin Reaction — DermLight  

Hand-foot Syndrome Clinical Trial

Official title:
Evaluating the Effectiveness of Photobiomodulation Therapy in the Management of Hand-foot Syndrome and Hand-foot Skin Reaction: A Single-arm Trial

Clinical Trial Summary

Hand-foot syndrome (HFS) is a side effect of chemotherapy. HFS is characterized by redness, swelling, and pain on the palms of the hands and/or soles of the feet, which can progress to blistering. Hand-foot skin reaction (HFSR) refers to symptoms affecting the hands and/or feet associated with multikinase inhibitors (TKIs). HFS and HFSR are painful complications that can lead to compromised daily activities, sleep-wake disturbance and impaired mobility, eventually decreasing Quality of Life (QoL). Photobiomodulation therapy (PBMT) is a non-invasive therapy based on the application of visible and/or near-infrared light produced by a laser diode or a light-emitting diode. The scientifically proven biologic effects of PBM are improved wound healing, and a reduction in pain, inflammation, and oedema. The aim of this study is to evaluate the effectiveness of PBMT in the management of HFS and HFSR.

Clinical Trial Description

The aim of this study is to evaluate the efficacy of PBMT in the management of HFS and HFSR in patients with cancer treated with chemotherapy or TKIs up to 2 weeks post-PBMT. Primary objective: The study seeks primarily to determine the effectiveness of PBMT in reducing the severity of HFS and HFSR in patients with cancer of different etiology undergoing chemotherapy or TKIs, diagnosed with HFS or HFSR (grade 1-3). Secondary objective 1 : HFS/HFSR-related symptoms A secondary aim of this study is to evaluate if PBMT and can reduce the HFS/HSFR-related symptoms during PBM treatment and up to 2 weeks post-PBMT Secondary Objective 2: Quality of life A secondary aim of this study is to evaluate if PBMT can improve the patients' QoL during PBM treatment and up to 2 weeks post-PBMT Secondary Objective 3: Patient satisfaction A secondary aim of this study is to evaluate if patients are satisfied with PBMT as a treatment for HFS and HFSR during the treatment sessions and up to 2 weeks post-PBMT Secondary Objective 4: PBM safety A secondary aim of this study is to evaluate the safety of PBM in oncologic patients up to 5 years post-PBMT. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04979078
Study type Interventional
Source Jessa Hospital
Contact Jeroen Mebis, MD, PhD
Phone +32 11 33 72 21
Email Jeroen.mebis@jessazh.be
Status Recruiting
Phase N/A
Start date January 12, 2022
Completion date August 2029
View Details
See also
  Status Clinical Trial Phase
Completed NCT04592731 - Acetylated Natural Nucleotides in Treating Hand-foot Syndrome N/A
Completed NCT05755646 - Ice Plant Intensive Cream for the Prevention of Hand-Foot Syndrome in Breast Cancer: Pilot Randomized Controlled Trial N/A
Completed NCT00446147 - Study of Pyridoxine for Hand-Foot Syndrome Phase 3
Completed NCT01609166 - Effectiveness Allopurinol Topical Agent Prevention Capecitabine-induced Hand-foot Syndrome Phase 2
Terminated NCT03173365 - The Effect of Topical Brimonidine Tartrate on Hand-foot Syndrome (HFS) in Cancer Patients Phase 2
Recruiting NCT05165069 - The Efficacy and Safety of Mecobalamin in the Prevention of Capecitabine Induced Hand Foot Syndrome Phase 3
Recruiting NCT05348278 - Urea Cream Prevention for Capecitabine Associated Hand Foot Syndrome Phase 2/Phase 3
Recruiting NCT04833998 - Hydration Based on Thoitaine, Aloe Vera and Calendula, in the Prevention of Hand-Foot Syndrome in Patients Using Capecitabine Phase 2
Not yet recruiting NCT05949307 - The Efficacy of Acupuncture and Laser Acupuncture in Treating Chemotherapy or Target Therapy-induced Hand-foot Syndrome N/A